

# Fontan-Associated Liver Disease: Screening, Management, and Transplant Consideration

Reviewed by: Andrew Yu

## **Epidemiology**

- Fontan-associated liver disease (FALD) describes spectrum of fibrosis and cirrhosis resulting from Fontan circulation
- Operation performed in congenital univentricular physiology (ex. hypoplastic left heart, tricuspid atresia, etc.)
- >900 Fontans performed/year in US in children ages 2-5
- 70,000 worldwide have undergone Fontan
- Only 1/3 of adult Fontan patients are with acceptable cardiac function and no end organ disease

### Procedure

- 3 Stages: Norwood, Glenn, and Fontan
- Norwood 1) creates new aorta that connects to the RV, 2) creates shunt between PA and RV (or aorta), 3) closes PDA, and 4) opens ASD
- Glenn connects SVC to PA and removes BT shunt
- Fontan connects IVC to PA
- Blood from SVC and IVC are diverted directly to pulmonary arteries, achieving total cavopulmonary connection


## Physiology

- Total cavopulmonary connection → high CVP, low CO, and low O2 saturation
- Passive, non-pulsatile pulmonary flow
   → liver congestion → shear stress on
   hepatic vasculature → sinusoidal
   fibrosis
- Reduced CO with hypoxia → centrilobular ischemia → further fibrosis
- Unclear if hemodynamics are related to progression of fibrosis

- Time since Fontan is the most important predictor of advanced FALD
- 100% of patients have histologic evidence of fibrosis.
- 40% have bridging fibrosis at 10 years post-Fontan


#### Norwood

1st Repair




#### **Bidirectional Glenn**

2<sup>nd</sup> Repair




## **Fontan**

3rd Repair



Guseh et al. Prenatal Diagnosis. 2020



Tellez et al. Annals of Hepatology. March 2018.

## **Diagnosis and Monitoring**

### · Serum biomarkers

- AST, ALT, ALP, bili, GGT rarely elevated
- INR only biomarker associated with high grade fibrosis (F3-F4)
- MELD-Na does not correlate with disease severity and is rarely elevated
- MELD-XI (excludes INR) correlated with biopsy-proven fibrosis


- Imaging Modalities
  - US, CT, or MRI to assess liver morphology and signs of portal hypertension
  - Nodularity does not necessarily = cirrhosis
  - Elastography can assess stiffness but unable to distinguish between passive congestion and fibrosis

## Liver biopsy

- Gold standard
- Use METAVIR or Congestive Hepatic Fibrosis Score (CHFS)
- Obtain at 10 years post Fontan

#### Liver Lesions

- Often have hypervascular nodules, large regenerative nodules, and focal nodular hyperplasia
- 3-15% of post Fontan develop HCC
- MRI helpful but diagnosing true HCC with LIRADS is challenging as congestive hepatopathy may affect contrast washout in delayed venous phase
- Liver biopsy usually necessary



Patient > 3 years post-Fontan with clinical concerns for chronic liver disease (any of the following):

- Ascites
- Splenomegaly
- Thrombocytopenia <100,000</li>
- · Gastrointestinal bleeding
- Jaundice
- · Failure to thrive/sarcopenia

- · Hepatology Referral
- Liver Biopsy (two passes, transvenous versus percutaneous with ascites drainage prior to biopsy)
- · MRI Elastography (baseline and then at least annually)
- Monitor liver labs at least q 3 months (INR, Bilirubin, ALP, ALT, AST)
- · EGD to assess for varices
- Treat/rule out cardiac causes of hepatic decompensation if present
- Consider early liver transplant referral for assessment for combined heart-liver transplant

# When does FALD require liver transplant?

- No guideline exists for when to do heart transplant vs combined heart-liver transplantation (CHLT) .
- Heart transplant is pursued in setting of failing Fontan.
- Liver transplant alone is not advised.
- If high grade fibrosis seen, would 1st try implementing strategies to lower R sided heart pressures and improve hepatic venous outflow.

# Considerations and Key Unknowns

- Degree of liver fibrosis does not correlate with risk of progression to decompensated cirrhosis and need for transplant.
- We cannot predict who with FALD, after heart transplant alone, may stabilize or regress their hepatic fibrosis vs who may decompensate.
- Long-term risk of developing HCC is unknown.
- There is reported discordance between explant liver histology and pretransplantation liver biopsy.
  - ~30% with more advanced fibrosis on explant
  - Can determine at time of transplantation if CHLT is needed with direct visualization of native liver

## **Heart Transplant Alone vs CHLT**

- · Overall survival is similar
- CHLT experience less rejection compared to heart alone
  - 20% of patients with congenital heart have allosensitization due to prior transfusion requirements and CHLT can overcome rejection
- Heart transplant recipients subsequently placed on liver transplant waiting list have high mortality

